[
  {
    "clause_index": 5,
    "start_char": 2691,
    "end_char": 3258,
    "original": "Sanofi Pasteur agrees to purchase and ADMA to manufacture [***] Batches of Product, which Batches will be produced over a period from Q3 2018 to Q3 2019. Attached hereto as Exhibit A is a detailed supply plan provided to ADMA by Sanofi Pasteur (the \u201cUpdated Supply Plan\u201d) that describes the agreed-upon timing for production of such Batches of Product, which supply plan is made an integral part hereof and shall be binding on the Parties. Prices for such [***] Batches of Product shall be in accordance with Section 3.2 of the Agreement (as amended in Amendment #2).",
    "ollama_generated": "ADMA agrees to manufacture, and Sanofi Pasteur undertakes to purchase [***] Batches of Product, which Batches will be produced by ADMA from Q3 2018 through Q3 2019. The detailed supply plan provided by Sanofi Pasteur to ADMA (the \u201cUpdated Supply Plan\u201d), attached hereto as Exhibit A, outlines the agreed-upon production timeline for such Batches of Product, and shall serve as a binding schedule for both parties. Any deviations from this schedule will require mutual agreement between the Parties. The prices for these [***] Batches of Product will be in accordance with Section 3.2 of the Agreement (as amended by Amendment #2).\n\nThis revision shifts some responsibility to Sanofi Pasteur regarding production scheduling and allows for flexibility in case of unforeseen circumstances requiring mutual agreement between the parties to alter the production schedule.",
    "contradiction_score": 0.00772026926279068,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 6,
    "start_char": 3258,
    "end_char": 3600,
    "original": "BPC Initials ___ Sanofi Pasteur Initials ___ Confidential treatment has been requested with respect to portions of this agreement as indicated by \u201c[***]\u201d and such confidential portions have been deleted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.",
    "ollama_generated": "Clause:\nBPC Initials ___ Sanofi Pasteur Initials ___ It is mutually agreed that certain sections of this agreement, designated by \"[***]\", are to be kept confidential and not disclosed to any third party. These confidential segments have been omitted from this document and retained separately for record-keeping purposes in accordance with Rule 24b-2 of the Securities Exchange Act of 1934, as amended, permitting such nondisclosure.",
    "contradiction_score": 0.039596788585186005,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 14,
    "start_char": 7156,
    "end_char": 7630,
    "original": "5. In consideration for certain quantities of Product that ADMA would have been contractually obligated to supply, and that Sanofi Pasteur would have been contractually obligated to purchase, under the Agreement, but that will now not be supplied and purchased as a result of the Parties\u2019 agreement in Section 2 above, Sanofi Pasteur agrees to pay ADMA an amount of seven million (7,000,000 USD) (the \u201cCompensation Fee\u201d) in five installments and will be invoiced as follows:",
    "ollama_generated": "5. Upon the mutual understanding that the Parties have forfeited their respective obligations under the Agreement to receive and deliver certain quantities of Product, Sanofi Pasteur consents to make a compensation payment to ADMA in the amount of seven million (7,000,000 USD) (the \"Compensation Fee\"), payable in five installments. The invoicing schedule for this Compensation Fee shall be as follows:\n\nThis clause reflects a slight shift in responsibility, where the parties have voluntarily waived their contractual obligations to supply and purchase Product under the Agreement, leading to Sanofi Pasteur agreeing to compensate ADMA instead.",
    "contradiction_score": 0.003771961433812976,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 21,
    "start_char": 9564,
    "end_char": 9642,
    "original": "7. The Parties further agree to amend Section 6.5 of the Agreement as follows:",
    "ollama_generated": "7. For the sake of clarity and adaptability, the Parties hereby consent to modify Section 6.5 of the Agreement in this manner:\n\n[New Clause]\n6.5 Modified: The Party responsible for any given action or obligation under the Agreement shall have the discretion to delegate such responsibility to a third party, provided that the delegated party possesses the necessary qualifications and complies with all applicable laws and regulations. In such cases, the initial Party shall remain accountable for the timely completion of the delegated task and shall ensure that the delegated party acts in a manner consistent with the Agreement's spirit and intent. The Parties acknowledge that this modification does not alter their mutual obligation to maintain open communication regarding all matters pertaining to the Agreement.",
    "contradiction_score": 0.003420214168727398,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 26,
    "start_char": 11201,
    "end_char": 12214,
    "original": "6.5 Limitation of Liability: In no event shall either party be liable to the other party for incidental, indirect, special and consequential or punitive damages, including without limitation any claims for damages based upon lost profits or lost business opportunity. Except for the obligation of indemnity as set forth in Section 6.1 (c) with respect to claims by third parties for personal injury, illness or death (but not including property damage) resulting from the manufacture of the Product by BPC, aggregate damages for which ADMA shall be liable to Sanofi Pasteur hereunder, including without limitation costs of Source Plasma yield loss and/or rejected Batches, shall not exceed [***] . All claims by Sanofi Pasteur for breach or default under this Agreement shall be brought within [***] year after the cause of action comes into existence or otherwise shall be waived. This limitation of liability will not apply for damages that result from the gross negligence or the willful misconduct of a Party.",
    "ollama_generated": "6.5 Limitation of Responsibility: Neither party shall be held responsible to the other for any consequential, indirect, incidental, special, punitive, or exemplary damages, nor for any claims pertaining to lost profits or business opportunities. However, ADMA's total liability towards Sanofi Pasteur in this Agreement, including but not limited to costs associated with Source Plasma yield loss and/or rejected Batches, will be capped at [***]. All claims by Sanofi Pasteur for breach or default under this Agreement must be brought within [***] years after the cause of action arises; otherwise, they shall be waived. This limitation of responsibility does not apply to damages resulting from the intentional misconduct or gross negligence on the part of either Party.",
    "contradiction_score": 0.1848399043083191,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 31,
    "start_char": 14409,
    "end_char": 14633,
    "original": "IN WITNESS WHEREOF , the parties hereby have caused this Amendment #3 to the Agreement to be executed and the persons signing below warrant that they are duly authorized to sign for and on behalf of their respective Parties.",
    "ollama_generated": "FOR THE RECORD, the parties mutually attest that it is within their respective authorities to sign this Amendment #3 to the Agreement, and by doing so, they confirm their binding obligation to the terms herein. The individuals signing below guarantee personal responsibility for any lack of authority to execute this document on behalf of their respective Parties.",
    "contradiction_score": 0.0022408757358789444,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 32,
    "start_char": 14635,
    "end_char": 14663,
    "original": "Made in two original copies.",
    "ollama_generated": "Executed in two identical, counterpart versions.\n\nThis change shifts the focus from the creation of two separate original documents to identical, counterpart versions that can be considered as a single agreement with mirror images. This adjustment may indicate a more flexible approach towards executing and exchanging signed copies.",
    "contradiction_score": 0.038685623556375504,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 33,
    "start_char": 14664,
    "end_char": 14684,
    "original": "Sanofi Pasteur, S.A.",
    "ollama_generated": "Sanofi Pasteur, S.A., shall have no liability for any claims arising out of the use or inability to use the product, except where such claim is directly attributable to Sanofi's gross negligence or willful misconduct. The User acknowledges and agrees that they are responsible for complying with all applicable laws and regulations regarding the use of this product.\n\n(Original clause: The User acknowledges and agrees that Sanofi Pasteur, S.A., shall not be liable for any claims arising out of the use or inability to use the product, except for claims resulting from Sanofi's breach of its material obligations under this Agreement.)",
    "contradiction_score": 0.019175125285983086,
    "kept": false,
    "reason": "low_contradiction"
  }
]